2.17
price up icon1.88%   0.04
after-market Handel nachbörslich: 2.17
loading
Schlusskurs vom Vortag:
$2.13
Offen:
$2.14
24-Stunden-Volumen:
4.86M
Relative Volume:
1.08
Marktkapitalisierung:
$437.52M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.0236
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+5.85%
1M Leistung:
+77.87%
6M Leistung:
+19.23%
1J Leistung:
+26.90%
1-Tages-Spanne:
Value
$2.13
$2.20
1-Wochen-Bereich:
Value
$2.00
$2.20
52-Wochen-Spanne:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Firmenname
Esperion Therapeutics Inc
Name
Telefon
734-887-3903
Name
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Mitarbeiter
304
Name
Twitter
@esperioninc
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
ESPR's Discussions on Twitter

Vergleichen Sie ESPR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
2.17 423.41M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
156.62 67.51B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.52 47.88B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.82 43.42B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.46 20.72B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.23 14.21B 2.99B 1.21B 1.13B 25.06

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-18 Eingeleitet Goldman Neutral
2024-12-17 Eingeleitet Cantor Fitzgerald Overweight
2024-06-20 Herabstufung BofA Securities Neutral → Underperform
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-08-01 Hochstufung Northland Capital Under Perform → Market Perform
2023-06-15 Hochstufung BofA Securities Underperform → Buy
2023-03-16 Herabstufung BofA Securities Neutral → Underperform
2023-03-16 Herabstufung Northland Capital Market Perform → Under Perform
2023-03-07 Hochstufung Credit Suisse Underperform → Neutral
2023-02-27 Fortgesetzt BofA Securities Neutral
2023-02-24 Hochstufung Jefferies Hold → Buy
2023-02-03 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-08-03 Herabstufung Credit Suisse Neutral → Underperform
2022-05-05 Hochstufung JP Morgan Underweight → Neutral
2022-03-10 Eingeleitet H.C. Wainwright Buy
2021-10-19 Herabstufung Credit Suisse Outperform → Neutral
2021-10-14 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-05-05 Herabstufung Stifel Buy → Hold
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-11 Eingeleitet Morgan Stanley Equal-Weight
2021-02-12 Herabstufung Jefferies Buy → Hold
2021-02-09 Herabstufung Goldman Neutral → Sell
2021-01-15 Herabstufung BofA Securities Buy → Neutral
2020-11-10 Hochstufung Credit Suisse Neutral → Outperform
2020-09-29 Fortgesetzt JP Morgan Underweight
2020-08-11 Herabstufung Credit Suisse Outperform → Neutral
2020-04-01 Fortgesetzt BofA/Merrill Buy
2020-03-17 Hochstufung Citigroup Neutral → Buy
2020-02-24 Herabstufung Northland Capital Outperform → Market Perform
2020-02-14 Herabstufung Citigroup Buy → Neutral
2019-09-16 Hochstufung Goldman Sell → Neutral
2019-05-29 Herabstufung Goldman Neutral → Sell
2019-05-06 Hochstufung BofA/Merrill Underperform → Neutral
2019-04-26 Hochstufung Goldman Sell → Neutral
2019-03-13 Hochstufung JP Morgan Underweight → Neutral
2019-01-07 Bestätigt Needham Strong Buy
2018-12-13 Eingeleitet Goldman Sell
2018-10-29 Hochstufung Northland Capital Market Perform → Outperform
2018-10-16 Eingeleitet BTIG Research Buy
2018-08-17 Hochstufung Citigroup Neutral → Buy
2018-07-11 Herabstufung Northland Capital Outperform → Market Perform
2018-05-03 Herabstufung JP Morgan Neutral → Underweight
2018-05-02 Herabstufung BofA/Merrill Buy → Underperform
Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

pulisher
Aug 20, 2025

Esperion rises after revenue beat, Q1 profitability expectation - MSN

Aug 20, 2025
pulisher
Aug 19, 2025

Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Detecting support and resistance levels for Esperion Therapeutics Inc.Stock Surge & Safe Entry Momentum Tips - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Chart based analysis of Esperion Therapeutics Inc. trendsWeekly Market Report & AI Forecasted Entry/Exit Points - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Is Esperion Therapeutics Inc. still worth holding after the dip2025 Short Interest & Community Consensus Picks - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Esperion Therapeutics soars amid vague takeover speculation - MSN

Aug 18, 2025
pulisher
Aug 17, 2025

Best data tools to analyze Esperion Therapeutics Inc. stockTrade Risk Report & Risk Controlled Daily Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Esperion Therapeutics Inc. stock outlook for YEARPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Market Movers & AI Based Trade Execution Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Applying sector rotation models to Esperion Therapeutics Inc.Market Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street Zen - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Pattern recognition hints at Esperion Therapeutics Inc. upsideStock Surge & Risk Adjusted Buy/Sell Alerts - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

What MACD signals say about Esperion Therapeutics Inc.July 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Real time scanner hits for Esperion Therapeutics Inc. explainedJuly 2025 Earnings & Smart Money Movement Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Will Esperion Therapeutics Inc. price bounce be sustainableCEO Change & Daily Market Momentum Tracking - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

What the charts say about Esperion Therapeutics Inc. today2025 Price Targets & Long Hold Capital Preservation Tips - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Is Esperion Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Stock Portfolio Risk Control - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Backtesting results for Esperion Therapeutics Inc. trading strategiesWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Is a relief rally coming for Esperion Therapeutics Inc. holdersDollar Strength & Free High Accuracy Swing Entry Alerts - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Signal strength of Esperion Therapeutics Inc. stock in tech scannersJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Can Esperion Therapeutics Inc. Regain Momentum After BreakdownJuly 2025 Rallies & Safe Entry Trade Reports - beatles.ru

Aug 14, 2025
pulisher
Aug 13, 2025

What earnings revisions data tells us about Esperion Therapeutics Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat

Aug 13, 2025
pulisher
Aug 12, 2025

Esperion Delays Q2 2025 Financial Report Filing - MSN

Aug 12, 2025
pulisher
Aug 12, 2025

Competitive Positioning of Esperion Therapeutics Inc.: Is It Leading or LaggingFree Intraday Trend Analysis for Fast Gains - Newser

Aug 12, 2025
pulisher
Aug 10, 2025

Published on: 2025-08-10 18:32:11 - beatles.ru

Aug 10, 2025
pulisher
Aug 10, 2025

FY2025 EPS Estimates for ESPR Boosted by Cantor Fitzgerald - Defense World

Aug 10, 2025
pulisher
Aug 09, 2025

Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru

Aug 09, 2025
pulisher
Aug 09, 2025

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street Zen - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

HC Wainwright Issues Positive Outlook for ESPR Earnings - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

Published on: 2025-08-08 10:01:24 - beatles.ru

Aug 08, 2025
pulisher
Aug 07, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan

Aug 07, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register

Aug 06, 2025
pulisher
Aug 06, 2025

What institutional flow reveals about Esperion Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks

Aug 06, 2025

Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Halladay Benjamin
Chief Financial Officer
Jul 17 '25
Sale
1.11
11
12
474,462
$29.75
price up icon 2.37%
$17.91
price up icon 2.40%
drug_manufacturers_specialty_generic RDY
$14.51
price up icon 0.62%
$10.65
price down icon 0.37%
$135.43
price up icon 0.11%
$312.23
price up icon 0.51%
Kapitalisierung:     |  Volumen (24h):